Table of Contents Table of Contents
Previous Page  106 / 140 Next Page
Information
Show Menu
Previous Page 106 / 140 Next Page
Page Background

Guía OncoSur de sarcomas de partes blandas

106

>

6. Le Cesne A, Antoine E, Spielmann M, et al. High-dose ifosfamide: circumvention of resistance to standard-dose

ifosfamide in advanced soft tissue sarcomas. J Clin Oncol. 1995;13(7):1600.

7. Demetri GD, von Mehren M, Jones RL, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic

Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Random-

ized Multicenter Clinical Trial. J Clin Oncol 2016;34(8):786-93.

8. Van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a ran-

domised, double-blind, placebo-controlled phase 3 trial. Lancet 2012;379:1879-86.

9. Schöffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with ad-

vanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet

2016;387(10028):1629.

10. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with

gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research

through Collaboration study 002. J Clin Oncol 2007;25:2755-63.

11. Pautier P, Floquet A, Penel N, et al. Randomized multicenter and stratified phase II study of gemcitabine alone

versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Na-

tionale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).

Oncologist 2012;17:1213-20.

12. García del Muro X, López-Pousa A, Maurel J, et al (2011) Randomized phase II study comparing gemcitabine

plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish

Group for Research on Sarcomas study. J Clin Oncol 2011;29(18):2528.

13. Demetri G, Blay JY, Casali PG. Advances and controversies in the management of soft tissue sarcomas. Future

Oncology 2017;13(Suppl 1):3-11.